熱門資訊> 正文
C4 Therapeutics定价1.25亿美元股票发行认股权证
2025-10-16 19:27
- C4 Therapeutics (NASDAQ:CCCC) priced an offering of 21.9M shares and 28.7M pre-funded warrants, each paired with Class A and Class B Warrants.
- Securities priced at $2.47/share or $2.4699/pre-funded warrant, with Class A and B Warrants exercisable at $2.22/share.
- Class A Warrants expire after 30 days post-clinical trigger or in 5 years; Class B Warrants expire in 5 years, with possible mandatory exercise conditions.
- Gross proceeds will be $125M initially, and up to $349.7M if all warrants are exercised.
- Proceeds will fund clinical trials of cemsidomide, R&D activities, and general corporate needs.
- Offering expected to close on or around October 17, 2025.
- CCCC shares down 4.5% premarket on Thursday.
More on C4 Therapeutics
- C4 Therapeutics, Inc. (CCCC) Presents at IMS Annual Meeting 2025 Oral Presentation - Slideshow
- C4 Therapeutics, Inc. (CCCC) Special Call - Slideshow
- C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple Myeloma Presented At IMS 2025 Transcript
- Seeking Alpha’s Quant Rating on C4 Therapeutics
- Historical earnings data for C4 Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
